Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 12, 2005, Pages 2560-2566

  Urso, Maria L ^a   Clarkson, Priscilla M ^a   Hittel, Dustin ^c   Hoffman, Eric P ^c   Thompson, Paul D ^b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b HARTFORD HOSPITAL   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cardiovascular pharmacology; Exercise; Gene expression

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; HEPTANOIC ACID DERIVATIVE; PROTEASOME; PYRROLE DERIVATIVE; UBIQUITIN;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DRUG MECHANISM; EXERCISE; GENE EXPRESSION; HUMAN; MALE; MUSCLE BIOPSY; MUSCLE INJURY; MYALGIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOLYSIS; SKELETAL MUSCLE; VASTUS LATERALIS MUSCLE; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MUSCLE DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; EXERCISE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUSCLE, SKELETAL; MUSCULAR DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UBIQUITIN;

EID: 33644802663     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000190608.28704.71     Document Type: Article

References (38)

1. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Coenzyme-A-reductase inhibitor treatment. Atherosclerosis. 1999;143: 459-460.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Jama. 1999;282: 2340-2346.
3. Sinzinger H. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation? Atherosclerosis. 2000;149:225.
4. Sinzinger H, Lupattelli G, Chehne F, Oguogho A, Furberg CD. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther. 2001;26:303-310.
5. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottolini AG. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem. 1990; 36:2145-2147.
6. Sica DA, Gehr TW. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol. 2002;11:48-55.
7. Sica DA, Gehr TW. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Curr Opin Nephrol Hypertens. 2002;11:123-133.
8. Fuhrmans V Bayer discloses higher death toll from Baycol. Wall Street Journal. 2002;January 21:A10.
9. Grundy SM. Statin therapy in older persons: pertinent issues. Arch Intern Med. 2002;162:1329-1331.
10. Thompson PD, Gadaleta PA, Yurgalevitch S, Cullinane E, Herbert PN. Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism. 1991;40:1333-1336.
11. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46:1206-1210.
12. Clarkson PM, Hubal MJ. Exercise-induced muscle damage in humans. Am J Phys Med Rehabil. 2002;81:S52-69.
13. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
14. Chen YW, Hubal MJ, Hoffman EP, Thompson PD, Clarkson PM. Molecular responses of human muscle to eccentric exercise. J Appl Physiol. 2003;95:2485-2494.
15. The Tumor Analysis Best Practices Working Group. Expression profiling - best practices for data generation and interpretation in clinical trials. Nat Rev Genet. 2004;5:229-237.
16. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001;98:31-36.
17. Seo J, Bakay M, Chen YW, Hilmer S, Shneiderman B, Hoffman EP. Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics. 2004;20:2534-2544.
18. Willoughby DS, Taylor M, Taylor L. Glucocorticoid receptor and ubiquitin expression after repeated eccentric exercise. Med Sci Sports Exerc. 2003;35:2023-2031.
19. Medina R, Wing SS, Haas A, Goldberg AL. Activation of the ubiquitin-ATP-dependent proteolytic system in skeletal muscle during fasting and denervation atrophy. Biomed Biochim Acta. 1991;50:347-356.
20. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001;98:14440-14445.
21. Lecker SH, Solomon V, Mitch WE, Goldberg AL Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr. 1999;129:227S-237S.
22. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3: 1014-1019.
23. Ordway GA, Neufer PD, Chin ER, DeMartino GN. Chronic contractile activity upregulates the proteasome system in rabbit skeletal muscle. J Appl Physiol. 2000;88:1134-1141.
24. Hunter RB, Stevenson E, Koncarevic A, Mitchell-Felton H, Essig DA, Kandarian SC. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. Faseb J. 2002;16:529-538.
25. Hasselgren PO, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg. 2001;233:9-17.
26. Taillandier D, Aurousseau E, Meynial-Denis D, Bechet D, Ferrara M, Cottin P, Ducastaing A, Bigard X, Guezennec CY, Schmid HP, et al. Coordinate activation of lysosomal, Ca 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle. Biochem J. 1996;316(Pt 1):65-72.
27. Phillips PS. Ezetimibe and statin-associated myopathy. Ann Intern Med. 2004;141:649.
28. Hoffman EP, Nader GA. Balancing muscle hypertrophy and atrophy. Nat Med. 2004;10:584-585.
29. Hittel DS, Kraus WE, Tanner CJ, Houmard JA, Hoffman EP. Exercise training increases electron and substrate shuttling proteins in muscle of overweight men and women with the metabolic syndrome. J Appl Physiol. 2005;98:168-179.
30. Mittel DS, Kraus WE, Hoffman EP. Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. J Physiol. 2003;548:401-410.
31. Du J, Hu Z, Mitch WE Cellular signals activating muscle proteolysis in chronic kidney disease: A two-stage process. Int J Biochem Cell Biol. 2005 Jun 24. [Epub ahead of print]
32. Lowe DA, Warren GL, Ingalls CP, Boorstein DB, Armstrong RB. Muscle function and protein metabolism after initiation of eccentric contraction-induced injury. J Appl Physiol. 1995;79:1260-1270.
33. Troseid M, Lappegard KT, Claudi T, Damas JK, Morkrid L, Brendberg R, Mollnes TE. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J. 2004; 25:349-355.
34. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Froland SS, Semb AG, Aukrust P. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol. 2003;41:1460-1467.
35. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci. 2002;23:482-486.
36. Bethin KE, Nagai Y, Sladek R, Asada M, Sadovsky Y, Hudson TJ, Muglia LJ. Microarray analysis of uterine gene expression in mouse and human pregnancy. Mol Endocrinol. 2003;17:1454-1469.
37. Noguchi S, Tsukahara T, Fujita M, Kurokawa R, Tachikawa M, Toda T, Tsujimoto A, Arahata K, Nishino I. cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet. 2003;12: 595-600.
38. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, Morsberger L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W. Multiple-laboratory comparison of microarray platforms. Nat Methods. 2005;2:345-350.